OncoQuest Inc., a privately held, cancer immunotherapy company announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office for patent protection of the schedule of administration of our monoclonal anti-CA-125 antibody, mAb-B43.13, now known as oregovomab, in a specific schedule in combination with carboplatin and paclitaxel in Stage III-IV ovarian cancer patients.
September 25, 2019
· 4 min read